Abstract
Most kinase inhibitors reported so far are designed to bind to a highly conserved ATP binding pocket in a competitive manner. In this case, inhibitors targeting the ATP pocket may crossreact with different kinases, as well as with other proteins that bind ATP, and this may cause undesirable side effects that would limit their clinical usefulness. In addition to the kinase selectivity issues, human ether-a-go-go-related gene (hERG) inhibition could be an obstacle to develop a kinase inhibitor as a safe drug. This paper will review the methods employed in the development of selective kinase inhibitors with several successful examples. These include medicinal chemistry efforts to conquer hERG inhibition problems as sometimes seen in kinase inhibitor programs.
Keywords: Protein Kinase, Inhibitors, ATP, human ether-a-go-go-related gene (hERG), drug, T- Type celcium channels Blockers
Mini-Reviews in Medicinal Chemistry
Title: Strategies for the Design of Selective Protein Kinase Inhibitors
Volume: 8 Issue: 12
Author(s): Masaaki Sawa
Affiliation:
Keywords: Protein Kinase, Inhibitors, ATP, human ether-a-go-go-related gene (hERG), drug, T- Type celcium channels Blockers
Abstract: Most kinase inhibitors reported so far are designed to bind to a highly conserved ATP binding pocket in a competitive manner. In this case, inhibitors targeting the ATP pocket may crossreact with different kinases, as well as with other proteins that bind ATP, and this may cause undesirable side effects that would limit their clinical usefulness. In addition to the kinase selectivity issues, human ether-a-go-go-related gene (hERG) inhibition could be an obstacle to develop a kinase inhibitor as a safe drug. This paper will review the methods employed in the development of selective kinase inhibitors with several successful examples. These include medicinal chemistry efforts to conquer hERG inhibition problems as sometimes seen in kinase inhibitor programs.
Export Options
About this article
Cite this article as:
Sawa Masaaki, Strategies for the Design of Selective Protein Kinase Inhibitors, Mini-Reviews in Medicinal Chemistry 2008; 8 (12) . https://dx.doi.org/10.2174/138955708786141043
DOI https://dx.doi.org/10.2174/138955708786141043 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prophylactic Surgery to Reduce the Risk of Developing Breast Cancer:Issues and Clinical Implications
Current Women`s Health Reviews Prognostic and Predictive Markers in Colorectal Cancer – The Role of New Genomic Technologies
Current Pharmacogenomics The Impact of Tumor Physiology on Camptothecin-Based Drug Development
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Human Telomerase by Antisense Oligonucleotides and Ribozymes: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design Dietary Lipids and Alzheimer’s Disease
Current Alzheimer Research Computational Approaches for Fragment-Based and De Novo Design
Current Topics in Medicinal Chemistry T Lymphocytes as Targets of Gene Transfer with Moloney-Type Retroviral Vectors
Current Gene Therapy Meet Our Editorial Board Member
Current Proteomics Nano-Hydroxyapatite Doped with Ho-166 as Drug Delivery System for Bone Cancer Therapy and Diagnosis: Developing a Theragnostic Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Role of microRNAs in Vascular Remodeling
Current Molecular Medicine Target Identification of Grape Seed Extract in Colorectal Cancer Using Drug Affinity Responsive Target Stability (DARTS) Technique: Role of Endoplasmic Reticulum Stress Response Proteins
Current Cancer Drug Targets Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets
Current Signal Transduction Therapy Building Successful Relationships in the PLCO Cancer Screening Trial
Reviews on Recent Clinical Trials Injectable Chitosan/β-Glycerophosphate System for Sustained Release: Gelation Study, Structural Investigation, and Erosion Tests
Current Drug Delivery Gene Therapy by Liver Transplantation and Single Stranded Oligonucleotides (SSOs) in Familial Amyloidotic Polyneuropathy (FAP)
Current Pharmacogenomics Current Progress in Sample Preparation for Two-Dimensional Electrophoresis in Proteomics
Current Proteomics Efflux Pump Inhibitors: A Novel Approach to Combat Efflux-Mediated Drug Resistance in Bacteria
Current Drug Targets Nano-Phytosome: A Developing Platform for Herbal Anti-Cancer Agents in Cancer Therapy
Current Drug Targets